Mirum Pharmaceuticals, Inc. MIRM Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Ionis PharmaceuticalsIONS

$1.11M-55.8%

Rhythm Pharmaceuticals, Inc.RYTM

——

BridgeBio PharmaBBIO

——

AmgenAMGN

——

Other financials

Income statement

See full

Revenue$159.9M+43.3%

Operating income-$789.5M-5,100%

Net income-$790.2M-5,284%

EPS (diluted)-$13.43-4,377%

Balance sheet

See full

Cash & equivalents$261.5M+43.5%

Total debt$13.5M+56.4%

Total equity$242.5M+4.0%

Total assets$890.9M+29.1%

Cash flow

See full

Operating cash flow-$228.8M-11,566%

CapEx$664.0K+1,520%

Free cash flow-$229.4M-11,360%

Valuation

See full

Market cap$6.53B+152%

Enterprise value$6.28B+162%

P/S11.5×+4.6×

Profitability

See full

Operating margin-139.8%-168pp

Net margin-140.2%-169pp

FCF margin-30.3%—

Returns & leverage

See full

Return on equity-335.8%-377pp

Debt / equity0.1×0.0×

Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s unrealized gains on investments?: Mirum Pharmaceuticals, Inc. (MIRM) reported unrealized gains on investments of $35K in Q1 2026.